BNB Plus Corp Dossier
Qualitative Analysis
Business overview
BNB Plus Corp. (NASDAQ: BNBX), formerly known as Applied DNA Sciences, Inc., is a Delaware-incorporated company that underwent a major strategic transformation in late 2025. The company transitioned to a Digital Asset Treasury (DAT) model focused on the accumulation, staking, and active yield-generation of Binance Coin (BNB) within the Binance ecosystem. Alongside its digital asset treasury operations, BNB Plus Corp. continues to operate its biopharmaceutical subsidiary, LineaRx, which develops and commercializes cell-free DNA production technologies (such as the LineaDNA platform) and enzymatic RNA manufacturing solutions for genetic medicine and diagnostic developers.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Shifted corporate focus to a digital asset treasury model centered on BNB, the native cryptocurrency of the Binance blockchain. The company employs non-directional yield approaches (such as native staking, Binance Launchpool, PancakeSwap LPs, and collateralized DeFi strategies) to generate an 8% to 12% annualized yield and compound BNB holdings over time.
Expected impact: Aims to outperform simple BNB buy-and-hold strategies, delivering direct, yield-enhanced exposure to the Binance ecosystem through a regulated U.S. vehicle.
A formal board-authorized review of strategic alternatives to maximize shareholder value. The review is led by Richard Shorten (Founder of Silvermine and Chairman of GlobalStake) and focuses on evaluating digital asset and AI infrastructure opportunities (including institutional yield generation and agentic AI payment mechanisms) as well as the monetization of LineaRx, Inc.
Expected impact: Potential execution of a merger, reverse merger, business combination, joint venture, or asset sale to maximize shareholder value.
A structured assessment to identify and execute potential monetization opportunities for the company's wholly-owned biopharmaceutical subsidiary, LineaRx, Inc., which achieved profitability in Q2 FY2026.
Expected impact: May include partnerships, licensing arrangements, asset sales, or other transactions designed to realize cash value from the therapeutic DNA production platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
GlobalStake, a SOC 2 Type II certified Web3 infrastructure company, is leading the strategic review of BNB Plus's business, assets, and capital structure, specifically evaluating digital asset and AI infrastructure opportunities.
Terms: Established in conjunction with the May 2026 convertible preferred stock financing; specific advisory fee terms were not publicly disclosed.